Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.

According to estimates form the U.S. Food and Drug Administration (FDA), 40 million men and 20 million women experience hair loss. In 2003, 31,737 people, 88% of them men, underwent hair ...

"He was my only sibling, and it was my job to protect him,” she tells PEOPLE ... Hair Falling Out Due to Alcoholism, Insomnia: 'My Body Was Like Enough' She's still learning how to live with ...

Hair loss affects millions of people worldwide. Although treatments do exist, these solutions are costly and not always effective. Looking for a more lasting and effective solution, scientists ...

has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2 ...

The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat ...

"Today's approval allows us to offer treatment with a CDK4/6 inhibitor [Kisqali] to a significantly broader group of people as a powerful tool that, combined with endocrine therapy, can help ...

"We continue to transform cancer care with Kisqali, building on its established profile in the metastatic setting and now helping a wide range of people as they strive to stay cancer-free ...